Impact of interleukin-1β antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: results of secondary endpoints from a randomized …
J Hensen, CP Howard, V Walter, T Thuren - Diabetes & metabolism, 2013 - Elsevier
Aims/hypothesis This study was conducted to determine the optimal monthly subcutaneous
dose of canakinumab (a human monoclonal anti-human IL-1β antibody) needed to improve
glucose control in metformin-treated patients with type 2 diabetes mellitus (T2DM). Methods
This was a parallel-group, randomized, double-blind, multicentre, placebo-controlled study
designed to assess the effect on HbA 1c and the safety/tolerability of four monthly doses of
canakinumab (5, 15, 50, or 150 mg) as an add-on to metformin over 4 months. Results …
dose of canakinumab (a human monoclonal anti-human IL-1β antibody) needed to improve
glucose control in metformin-treated patients with type 2 diabetes mellitus (T2DM). Methods
This was a parallel-group, randomized, double-blind, multicentre, placebo-controlled study
designed to assess the effect on HbA 1c and the safety/tolerability of four monthly doses of
canakinumab (5, 15, 50, or 150 mg) as an add-on to metformin over 4 months. Results …